Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?

Issues in Mental Health Nursing

Volumn 30, Issue 12, 2009, Pages 803-805

  Housel, Audrey K ^a   Waterbury, Nancee ^a   Argo, Tami R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; METFORMIN; NEUROLEPTIC AGENT; ROSIGLITAZONE;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; METABOLIC SYNDROME X; NURSING; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 70450201568     PISSN: 01612840     EISSN: 10964673     Source Type: Journal    
DOI: 10.3109/01612840903276712     Document Type: Article

References (10)

1. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry, 156(11), 1686-1696.
2. Baptista, T., Martinez, J., Lacruz, A., Rangel, N., Beaulieu, S., Serrano, A., Araṕe,Y.,Martinez, M., deMendoza, S., Teneud, L.,& Herńandez, L. (2006). Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Canadian Journal of Psychiatry, 51(3), 192-196.
3. Baptista, T., Rangel, N., El Fakih, Y., Uzćategui, E., Galeazzi, T., Beaulieu, S., & Araujp de Baptista, E. (2009). Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: A pilot doubleblind, placebo-controlled, 12-week trial. Pharmacopsychiatry, 42, 14-19.
4. Dwyer, D. S., & Donohoe, D. (2003). Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacology, Biochemistry and Behavior, 75, 255-260.
5. Elias, A. N., & Hofflich, H. (2008). Abnormalities in glucose metabolism with patients with schizophrenia treated with atypical antipsychotic medications. The American Journal of Medicine, 121(2), 98-104.
6. Newcomer, J. W., & Haupt, D. W. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry, 51(8), 480-491.
7. Sacher, J., Mossaheb, N., Spindelegger, C., Klein, N., Geiss-Granadia, T., Sauermann, R., Lackner, E., Joukhadar, C., Müller, M., & Kasper, S. (2008). Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology, 33, 1633-1641. doi:10.1038/sj.npp. 1301541 (Pubitemid 351684708)
8. Sowell, M. O., Mukhopadhyay, N., Cavazzoni, P., Shankar, S., Steinberg, H. O., & Breier, A. (2002). Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. The Journal of Clinical Endocrinology & Metabolism, 87, 2918-2923.
9. Wu, R.-R., Zhao, J.-P., Guo, X.-F., He, Y.-Q., Fang, M.-S., Guo,W.-B., Chen, J.-D., & Li, L.-H. (2008). Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: A doubleblind, placebo-controlled study. American Journal of Psychiatry, 165, 352-358.
10. Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, X.-F., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. Journal of the American Medical Association, 299(2), 185-193.